Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05312385 · ClinicalTrials.gov registry record · Phase 3

Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU1)

A Phase 3 study of Sedation, sponsored by Sedana Medical.

Active
Registry status
Phase 3
Development phase
235
Enrollment target
14
Study locations

NCT05312385: Active Phase 3 study of Sedation, sponsored by Sedana Medical.

NCT05312385 is a Phase 3 study of Sedation that is active but no longer recruiting, run by Sedana Medical. The registered enrollment target is 235 participants, below the 100,166-participant average among 12 other Sedation trials with a reported enrollment target (100% lower). The trial reports 14 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05312385, a Phase 3 study of Sedation, is active but no longer recruiting, sponsored by Sedana Medical.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
235 participants
Enrollment target
14
Study locations

Study Summary

This is a study to compare safety and efficacy of inhaled isoflurane administered via the Sedaconda ACD-S device system versus intravenous propofol for sedation of mechanically ventilated patients in the Intensive Care Unit (ICU) setting.

Primary Outcome

The Target Range is RASS -1 to -4. The Richmond Agitation-Sedation Scale (RASS) is used to measure the level of agitation or sedation in patients, particularly in critical care settings. It is a 10-point scale ranging from -5 to +4: +4 Combative - Violent, immediate danger to staff. +3 Very agitated - Pulls or removes tubes or catheters; aggressive. +2 Agitated - Frequent non-purposeful movement, fights ventilator. +1 Restless - Anxious but movements are not aggressive. 0 Alert and calm. -1 Dr

Conditions Studied

Interventions

  • DRUG Propofol
  • DRUG Isoflurane

Study Locations (14)

Texas

  • University of Texas Southwestern Medical Center - Dallas
  • Houston Methodist Hospital - Houston
  • MD Anderson Cancer Center - Houston

Massachusetts

  • Tufts Medical Center - Boston
  • The Brigham and Women´s Hospital - Boston

Ohio

  • University of Cincinnati - Cincinnati
  • The Cleveland Clinic Foundation - Cleveland

Colorado

  • University of Colorado Anschutz Medical Campus - Aurora

Georgia

  • Emory University - Atlanta

Illinois

  • University of Chicago - Chicago

Minnesota

  • Mayo Clinic - Rochester

Tennessee

  • Vanderbilt University Medical Center - Nashville

Trial Details

FieldValue
Enrollment Target 235 participants
Start Date 2022-04-28
Est. Completion 2024-10-30
Phase Phase 3
Sedana Medical

3 total trials

What the registry record for NCT05312385 still lists

NCT05312385 is an interventional study that assigns participants to a tested intervention. The registered 235 participants enrollment target is mid-sized for trials with a published cap, below the 100,166-participant average among 12 other Sedation trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Sedation appearing as the primary indexed condition, and to 2 interventions - of which Propofol is the first listed.

NCT05312385 lists 14 locations in 10 states (Texas, Massachusetts, Ohio).

Frequently Asked Questions

What is clinical trial NCT05312385 about?

NCT05312385 is a clinical study titled "Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU1)". This is a study to compare safety and efficacy of inhaled isoflurane administered via the Sedaconda ACD-S device system versus intravenous propofol for sedation of mechanically ventilated patients in the Intensive Care Unit (ICU) setting.

What is the current status of trial NCT05312385?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 235 participants. The study started on 2022-04-28. Estimated completion is 2024-10-30.

What conditions does trial NCT05312385 study?

This clinical trial studies the following conditions: Sedation.

What interventions are being tested in trial NCT05312385?

The interventions under investigation include: Propofol (DRUG), Isoflurane (DRUG).

Who is sponsoring clinical trial NCT05312385?

This trial is sponsored by Sedana Medical, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05312385 being conducted?

This trial has 14 study locations across Colorado, Georgia, Illinois, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sedation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05312385's enrollment target sits among peer trials

235 6th of 12 higher than 7 of 12 other Sedation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sedation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01524211 · 235 participants · NA

    Evaluation of Branch Endografts in the Treatment of Aortic Aneurysms

  • NCT05316155 · 235 participants · Phase 1

    Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

  • NCT05353569 · 235 participants · NA

    Coherent Optical Detection of Middle Ear Disease

  • NCT05390918 · 235 participants · NA

    Targeting Adolescent Insomnia to Lessen Overall Risk of Suicidal Behavior

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05312385, the US trial registry maintained by the National Library of Medicine. NCT05312385 (mid enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.